Holen Sie sich die Stockscreener-App
101.11
3.83%
3.73
Handel nachbörslich:
101.66
0.55
+0.54%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt ILMN?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$97.38
Offen:
$98.2
24-Stunden-Volumen:
1.67M
Relative Volume:
0.73
Marktkapitalisierung:
$15.54B
Einnahmen:
$4.34B
Nettoeinkommen (Verlust:
$-965.00M
KGV:
-16.66
EPS:
-6.07
Netto-Cashflow:
$869.00M
1W Leistung:
+7.07%
1M Leistung:
+1.87%
6M Leistung:
-0.66%
1J Leistung:
-15.54%
1-Tages-Spanne:
$98.02
$101.37
1-Wochen-Bereich:
$93.32
$101.37
52-Wochen-Spanne:
$68.70
$156.66
Illumina Inc Stock (ILMN) Company Profile
Firmenname
Illumina Inc
Sektor
Branche
Telefon
(858) 202-4500
Adresse
5200 ILLUMINA WAY, SAN DIEGO, CA
Vergleichen Sie ILMN mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ILMN
Illumina Inc
|
101.11 | 15.00B | 4.34B | -965.00M | 869.00M | -6.07 |
|
TMO
Thermo Fisher Scientific Inc
|
484.79 | 174.60B | 43.21B | 6.58B | 6.17B | 17.29 |
|
DHR
Danaher Corp
|
209.14 | 143.04B | 24.01B | 3.41B | 4.86B | 4.70 |
|
IDXX
Idexx Laboratories Inc
|
663.92 | 52.17B | 4.04B | 985.66M | 774.34M | 12.01 |
|
A
Agilent Technologies Inc
|
120.29 | 32.42B | 6.63B | 1.17B | 1.19B | 4.05 |
|
IQV
Iqvia Holdings Inc
|
190.23 | 30.62B | 15.50B | 1.33B | 2.16B | 7.34 |
Illumina Inc Stock (ILMN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-11 | Herabstufung | Scotiabank | Sector Outperform → Sector Perform |
| 2025-03-04 | Bestätigt | Citigroup | Neutral |
| 2025-02-28 | Herabstufung | HSBC Securities | Buy → Hold |
| 2025-02-10 | Herabstufung | Barclays | Equal Weight → Underweight |
| 2025-02-07 | Herabstufung | TD Cowen | Buy → Hold |
| 2024-12-11 | Herabstufung | Citigroup | Buy → Neutral |
| 2024-11-12 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2024-10-17 | Hochstufung | HSBC Securities | Hold → Buy |
| 2024-08-28 | Hochstufung | Argus | Hold → Buy |
| 2024-08-16 | Hochstufung | Daiwa Securities | Neutral → Buy |
| 2024-08-14 | Hochstufung | Barclays | Underweight → Equal Weight |
| 2024-08-14 | Hochstufung | TD Cowen | Hold → Buy |
| 2024-07-10 | Hochstufung | Citigroup | Neutral → Buy |
| 2024-06-03 | Fortgesetzt | Jefferies | Hold |
| 2024-01-16 | Herabstufung | HSBC Securities | Buy → Hold |
| 2024-01-04 | Herabstufung | TD Cowen | Outperform → Market Perform |
| 2023-12-18 | Hochstufung | Scotiabank | Sector Perform → Sector Outperform |
| 2023-12-15 | Hochstufung | Bernstein | Underperform → Mkt Perform |
| 2023-12-14 | Eingeleitet | Guggenheim | Buy |
| 2023-12-14 | Eingeleitet | Stephens | Overweight |
| 2023-12-13 | Eingeleitet | Wolfe Research | Outperform |
| 2023-12-12 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2023-12-11 | Hochstufung | Citigroup | Sell → Neutral |
| 2023-11-10 | Herabstufung | Canaccord Genuity | Buy → Hold |
| 2023-09-28 | Eingeleitet | Bernstein | Underperform |
| 2023-07-05 | Fortgesetzt | JP Morgan | Neutral |
| 2023-01-25 | Herabstufung | Argus | Buy → Hold |
| 2023-01-05 | Eingeleitet | Scotiabank | Sector Perform |
| 2022-12-12 | Herabstufung | Citigroup | Neutral → Sell |
| 2022-12-07 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2022-10-04 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2022-09-28 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2022-08-25 | Eingeleitet | Credit Suisse | Neutral |
| 2022-07-13 | Herabstufung | Barclays | Equal Weight → Underweight |
| 2022-01-18 | Hochstufung | Stifel | Hold → Buy |
| 2022-01-11 | Hochstufung | Barclays | Underweight → Equal Weight |
| 2022-01-07 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2022-01-06 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2022-01-06 | Fortgesetzt | Piper Sandler | Overweight |
| 2021-10-15 | Fortgesetzt | Cowen | Outperform |
| 2021-08-19 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2021-06-01 | Hochstufung | Evercore ISI | Underperform → In-line |
| 2021-03-31 | Herabstufung | Atlantic Equities | Overweight → Neutral |
| 2021-03-31 | Hochstufung | Canaccord Genuity | Hold → Buy |
| 2021-03-03 | Eingeleitet | Barclays | Underweight |
| 2020-12-22 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2020-12-17 | Hochstufung | BTIG Research | Neutral → Buy |
| 2020-10-13 | Herabstufung | Guggenheim | Buy → Neutral |
| 2020-09-30 | Eingeleitet | Atlantic Equities | Overweight |
| 2020-09-29 | Herabstufung | Wolfe Research | Outperform → Peer Perform |
| 2020-09-22 | Herabstufung | Stifel | Buy → Hold |
| 2020-09-22 | Herabstufung | UBS | Buy → Neutral |
| 2020-09-21 | Hochstufung | Guggenheim | Neutral → Buy |
| 2020-09-21 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2020-09-09 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2020-08-07 | Herabstufung | Evercore ISI | In-line → Underperform |
| 2020-08-07 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2020-07-07 | Herabstufung | Guggenheim | Buy → Neutral |
| 2020-04-24 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-04-21 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2020-01-08 | Eingeleitet | Wells Fargo | Underweight |
| 2020-01-07 | Eingeleitet | Citigroup | Buy |
| 2020-01-02 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2019-11-15 | Eingeleitet | Stifel | Buy |
| 2019-10-25 | Eingeleitet | Guggenheim | Buy |
Alle ansehen
Illumina Inc Aktie (ILMN) Neueste Nachrichten
Now that NGS is more affordable, how can we make it easier? - Illumina
Illumina’s Q2 Earnings Call: Our Top 5 Analyst Questions - Yahoo Finance
[Latest] US Personalized Medicine Market Size/Share Worth USD 252.93 Billion by 2034 at a 17.32% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis) - GlobeNewswire Inc.
Centene, RadNet, Evolent Health, Illumina, and Charles River Laboratories Shares Are Soaring, What You Need To Know - Yahoo Finance
Illumina Sees Future Rebound in China Sales - San Diego Business Journal
Daiwa Securities Downgrades Illumina to Neutral From Outperform, Adjusts Price Target to $94 From $124 - MarketScreener
US Personalized Medicine Market Trends and Company Analysis - GlobeNewswire
US Personalized Medicine Market Trends and Company Analysis Report 2025-2033 Featuring Abbott, GE, Aadi Bioscience, Illumina, QIAGEN, Eli Lilly and Co, Takeda, AbbVie, F. Hoffmann-La Roche - Yahoo Finance
How Illumina Inc. stock performs during market volatilityMaximum Yield Stock Screener - classian.co.kr
Standard BioTools Announces SomaLogic Sale to Illumina - TipRanks
Latest Cybersecurity False Claims Act Settlement with Diagnostics Provider Focuses on Sensitive Health Systems - Inside Privacy
Illumina price leans on SMA supportForecast today11-08-2025 - Economies.com
DNA Microarray Market to Grow at 9% CAGR, Driven by Personalized - openPR.com
Single Cell Genome Sequencing Market is evolving rapidly Through 2025 To 2032 | Illumina, Inc., Fludigim Corporation - openPR.com
Is Illumina Inc. a strong growth stockEarnings Surprise Driven Picks - thegnnews.com
What makes Illumina Inc. stock price move sharplyMulti-Sector Diversified Watchlist - thegnnews.com
What are analysts’ price targets for Illumina Inc.Weekly Oversold Bounce Candidates - thegnnews.com
DOJ Settlement With Medical Technology Company Signals Expanding Cybersecurity FCA Risk for Life Sciences Companies - JD Supra
Illumina (NASDAQ:ILMN) Strong Profits May Be Masking Some Underlying Issues - simplywall.st
DOJ Secures First of Its Kind Cybersecurity False Claims Act Settlement - JD Supra
Bioinformatics Market Booms with Rapid Growth Expected by 2032 | Active Motif, Inc., Illumina - openPR.com
Illumina Reaches $9.8M Deal in Cybersecurity False Claims Probe - Homeland Security Today
Illumina Stock Slides 0.69 as Mixed Analyst Reactions Highlight 490th-Ranked Volume Amid Profitability Surge and Growth Doubts - AInvest
Illumina pays $9.8 million to settle DOJ claims over cybersecurity failures in government contracts - teiss
“False” Sense of Security: DOJ Announces False Claims Act Settlements Related to Failure to Comply with Cybersecurity Requirements - JD Supra
Does Illumina (ILMN) have an Attractive Risk-Reward Opportunity for Long-Term Investors? - MSN
Illumina Inc. to Pay $9.8M to Resolve False Claims Act Allegations Arising from Cybersecurity Vulnerabilities in Genomic Sequencing Systems - Sierra Sun Times
Illumina (ILMN) Reliance on International Sales: What Investors Need to Know - Yahoo Finance
Illumina, Inc. Just Recorded A 76% EPS Beat: Here's What Analysts Are Forecasting Next - simplywall.st
DOJ reaches USD 9.8M settlement with Illumina - Medical Buyer
Genomic Systems Maker Settles Cybersecurity Lawsuit - Manufacturing Business Technology
DOJ reaches $9.8M settlement with Illumina over cyber whistleblower claims - MedTech Dive
Unexpected Trends Reshaping the U.S. Genomics Market by 2032 - openPR.com
Insider Buying Surges at BEEX Holdings: Chubb and Illumina Lead the Way - AInvest
How the U.S. Precision Medicine Market Will Evolve by 2032 - openPR.com
Illumina’s SomaLogic acquisition may face GRAIL-like regulatory hurdles - ION Analytics
Is Illumina, Inc. (NASDAQ:ILMN) Potentially Undervalued? - au.finance.yahoo.com
Multi-Omics Market to Surpass US$33.25 Billion by 2033, Driven - openPR.com
Illumina Second Quarter 2025 Earnings: EPS Beats Expectations - Yahoo Finance
Illumina: The Stock Is Still Undervalued (NASDAQ:ILMN) - Seeking Alpha
Illumina Settles Allegations of Cyber Vulnerabilities in Genomic Sequencing for $9.8M - Claims Journal
What catalysts could drive Illumina Inc. stock higher in 2025Capitalize on market trends with confidence - Jammu Links News
What is Illumina Inc. company’s growth strategyGame-changing returns - jammulinksnews.com
What are Illumina Inc. company’s key revenue driversSuperior stock growth - Jammu Links News
Should I hold or sell Illumina Inc. stock in 2025Extraordinary market timing - Jammu Links News
Illumina, Inc.'s (NASDAQ:ILMN) Stock Is Going Strong: Have Financials A Role To Play? - simplywall.st
How does Illumina Inc. compare to its industry peersBuild a balanced portfolio for long-term success - Jammu Links News
Published on: 2025-08-03 17:43:00 - Jammu Links News
What is the dividend policy of Illumina Inc. stockBreakthrough profits - Jammu Links News
Illumina Inc. Stock Analysis and ForecastDiscover stock picks with superior returns - Jammu Links News
How strong is Illumina Inc. company’s balance sheetInvest confidently with professional guidance - Jammu Links News
Finanzdaten der Illumina Inc-Aktie (ILMN)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.96%
1.32%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):